PL3274366T3 - Chimeryczny receptor antygenowy - Google Patents

Chimeryczny receptor antygenowy

Info

Publication number
PL3274366T3
PL3274366T3 PL16712424T PL16712424T PL3274366T3 PL 3274366 T3 PL3274366 T3 PL 3274366T3 PL 16712424 T PL16712424 T PL 16712424T PL 16712424 T PL16712424 T PL 16712424T PL 3274366 T3 PL3274366 T3 PL 3274366T3
Authority
PL
Poland
Prior art keywords
antigen receptor
chimeric antigen
chimeric
receptor
antigen
Prior art date
Application number
PL16712424T
Other languages
English (en)
Inventor
Martin PULÉ
Shaun CORDOBA
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of PL3274366T3 publication Critical patent/PL3274366T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16712424T 2015-03-23 2016-03-22 Chimeryczny receptor antygenowy PL3274366T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1504840.8A GB201504840D0 (en) 2015-03-23 2015-03-23 Chimeric antigen receptor
PCT/GB2016/050795 WO2016151315A1 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor
EP16712424.7A EP3274366B8 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
PL3274366T3 true PL3274366T3 (pl) 2020-06-15

Family

ID=53052211

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16712424T PL3274366T3 (pl) 2015-03-23 2016-03-22 Chimeryczny receptor antygenowy

Country Status (21)

Country Link
US (1) US11058722B2 (pl)
EP (1) EP3274366B8 (pl)
JP (3) JP6675417B2 (pl)
KR (1) KR102174280B1 (pl)
CN (1) CN107406518B (pl)
AU (1) AU2016238583B2 (pl)
BR (1) BR112017018252A2 (pl)
CA (1) CA2978852C (pl)
CL (1) CL2017002413A1 (pl)
DK (1) DK3274366T3 (pl)
ES (1) ES2773527T3 (pl)
GB (1) GB201504840D0 (pl)
HU (1) HUE047929T2 (pl)
IL (1) IL254254B (pl)
MX (1) MX371384B (pl)
PL (1) PL3274366T3 (pl)
PT (1) PT3274366T (pl)
RU (1) RU2752880C2 (pl)
SG (1) SG11201706940QA (pl)
WO (1) WO2016151315A1 (pl)
ZA (1) ZA201705682B (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
AU2018246235B2 (en) 2017-03-27 2023-12-21 National University Of Singapore Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP2020511992A (ja) * 2017-03-29 2020-04-23 サニーブルック リサーチ インスティテュート 遺伝子組換えｔ細胞調節分子およびその使用方法
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN110914289B (zh) 2017-05-12 2024-05-14 克里斯珀医疗股份公司 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
JP2021500930A (ja) 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｐボディ−多価標的結合物質
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019193476A1 (en) 2018-04-02 2019-10-10 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
IL278348B2 (en) 2018-05-11 2025-03-01 Crispr Therapeutics Ag Methods and preparations for treating cancer
US11963981B2 (en) 2018-05-15 2024-04-23 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CN112930186A (zh) 2018-08-16 2021-06-08 纪念斯隆-凯特琳癌症中心 基于亮氨酸拉链的组合物和使用方法
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
JP7458382B2 (ja) 2018-09-27 2024-03-29 オートラス リミテッド キメラ抗原受容体
EP3860642A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CA3109747A1 (en) * 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
EP3927352A4 (en) * 2019-02-21 2023-06-14 Arbele Limited ARTIFICIAL IMMUNOSURVEILLANCE CHEMICAL ANTIGEN RECEPTORS (AI-CAR) AND CELLS EXPRESSING THEM
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202017649D0 (en) 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
KR20230148837A (ko) 2021-02-25 2023-10-25 라이엘 이뮤노파마, 인크. Ror1 표적화 키메라 항원 수용체
US20250288672A1 (en) * 2021-03-24 2025-09-18 Raymond Liu Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) * 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2024019961A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cd2 recruiting chimeric antigen receptors and fusion proteins
TW202540428A (zh) 2024-01-26 2025-10-16 美商雷傑納榮製藥公司 使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2010102518A1 (zh) 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
KR101156085B1 (ko) * 2010-01-29 2012-06-20 국립암센터 ４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도
US10745467B2 (en) * 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
KR101956751B1 (ko) * 2011-10-07 2019-03-11 고쿠리츠다이가쿠호진 미에다이가쿠 키메라 항원 수용체
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
WO2014039523A1 (en) 2012-09-04 2014-03-13 Cellectis Multi-chain chimeric antigen receptor and uses thereof
SI3613439T1 (sl) * 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
WO2015095895A1 (en) * 2013-12-20 2015-06-25 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
CN113307880B (zh) 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor

Also Published As

Publication number Publication date
EP3274366B8 (en) 2020-02-12
MX2017010552A (es) 2018-03-14
WO2016151315A1 (en) 2016-09-29
IL254254B (en) 2021-04-29
ES2773527T3 (es) 2020-07-13
BR112017018252A2 (pt) 2018-04-10
AU2016238583A1 (en) 2017-09-28
AU2016238583B2 (en) 2020-08-13
CN107406518B (zh) 2022-02-01
JP2020048588A (ja) 2020-04-02
KR20180009738A (ko) 2018-01-29
HUE047929T2 (hu) 2020-05-28
US11058722B2 (en) 2021-07-13
KR102174280B1 (ko) 2020-11-04
CA2978852A1 (en) 2016-09-29
EP3274366B1 (en) 2019-12-11
GB201504840D0 (en) 2015-05-06
JP6675417B2 (ja) 2020-04-01
DK3274366T3 (da) 2020-02-10
JP2023021396A (ja) 2023-02-10
CA2978852C (en) 2021-10-19
JP2018510639A (ja) 2018-04-19
NZ735267A (en) 2021-04-30
RU2752880C2 (ru) 2021-08-11
CL2017002413A1 (es) 2018-03-16
EP3274366A1 (en) 2018-01-31
US20180050065A1 (en) 2018-02-22
SG11201706940QA (en) 2017-09-28
CN107406518A (zh) 2017-11-28
ZA201705682B (en) 2018-12-19
IL254254A0 (en) 2017-10-31
RU2017132978A3 (pl) 2019-06-24
PT3274366T (pt) 2020-01-30
RU2017132978A (ru) 2019-04-08
MX371384B (es) 2020-01-28

Similar Documents

Publication Publication Date Title
IL280917B (en) Cs1 targeted chimeric antigen receptor-modified t cells
PL3274366T3 (pl) Chimeryczny receptor antygenowy
IL251030B (en) Chimeric antigen receptors
DK3294764T3 (da) Kimæriske antigenreceptor sammensætninger
IL257234A (en) Chimeric cytokine receptor
CL2016002196A1 (es) Receptor antigénico quimérico
IL251963A0 (en) Anti-pd-1 antibodies
PL3628687T3 (pl) Chimeryczne receptory antygenowe bcma
GB201503742D0 (en) Chimeric antigen receptor
GB201617290D0 (en) Novel chimeric antigen receptors
PL3230310T3 (pl) Chimeryczne receptory antygenowe anty-cd70
GB201607968D0 (en) Chimeric antigen receptor
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
GB201610512D0 (en) Chimeric antigen receptor
EP3604344A4 (en) CHEMICAL ANTIGENIC RECEPTOR
HUE054148T2 (hu) Anti-ORAI1 antitest
LT3126391T (lt) Hpa-1a antikūnai
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
GB201519900D0 (en) Chimeric antigen receptor
GB201612844D0 (en) Chimeric antigen receptor
GB201612533D0 (en) Chimeric antigen receptor
GB201604387D0 (en) Chimeric antigen receptor
BR112017002234A2 (pt) anticorpos anti-pd-l1
GB201409761D0 (en) Chimeric antigen receptor
GB201403481D0 (en) Chimeric antigen receptor